Advertisement
GKOS vs NTRA
Which Stock Would AI Choose? Glaukos Corporation (GKOS) vs. Natera, Inc. (NTRA) Stock Comparison
Key Takeaways
- GKOS (Glaukos) is an ophthalmology medical technology company, while NTRA (Natera) is a molecular diagnostics leader — two high-growth healthcare names with very different business models.
- In their most recent quarters, GKOS grew revenue roughly 50% year over year to $185.6 million, while NTRA grew about 38% to approximately $753 million.
- GKOS remains unprofitable on a net basis, whereas NTRA has recently transitioned to profitability, strengthening its fundamental profile.
- Both companies raised full-year revenue guidance in recent weeks, reflecting accelerating commercial momentum.
- NTRA trades near its 52-week high after a roughly 75% year-to-date advance; GKOS has also rallied strongly but has shown more pronounced single-session volatility.
- The two stocks carry different risk profiles, with GKOS facing reimbursement and insider-selling overhangs and NTRA facing pricing and competitive dynamics in oncology diagnostics.
Introduction
Investors weighing high-growth healthcare equities frequently encounter two distinct narratives: GKOS, a medical device innovator transforming glaucoma and corneal care, and NTRA, a diagnostics company reshaping cancer monitoring through liquid biopsy. This stock comparison is relevant for growth-oriented traders and investors evaluating relative performance, market positioning, and the durability of momentum across two very different segments of the healthcare economy. Although both companies deliver double-digit revenue growth and have outperformed broader benchmarks, their business models, profitability timelines, and risk exposures diverge meaningfully, making a side-by-side assessment valuable for portfolio allocation decisions.
GKOS Overview and Recent Performance
Glaukos Corporation (GKOS) develops ophthalmic medical technologies for glaucoma, corneal disorders, and retinal diseases. Its growth engine is iDose TR, a sustained-release glaucoma implant that has driven rapid adoption, alongside the recent U.S. launch of Epioxa, a first-of-its-kind epithelium-on corneal cross-linking therapy for keratoconus. In its most recent quarter, revenue rose about 50% year over year to $185.6 million, prompting management to raise full-year 2026 revenue guidance to a range of $680 million to $700 million.
Recent market activity has been mixed. The stock has delivered a strong year-to-date advance and trades well above its 52-week low, but recent weeks brought volatility: an insider sale by a senior executive briefly overshadowed positive late-stage Epioxa trial data, triggering a sharp single-day pullback. The shares subsequently recovered as Phase 4 data showing iDose TR's efficacy and an analyst price-target increase renewed confidence. Sentiment remains broadly constructive, though the company is still reporting net losses, with profitability contingent on continued execution and reimbursement stability.
NTRA Overview and Recent Performance
Natera, Inc. (NTRA) is a molecular diagnostics company focused on genetic testing across women's health, oncology, and organ health. Its flagship product, Signatera, is a tumor-informed molecular residual disease (MRD) test used to detect minimal traces of cancer in the blood after treatment. In its latest quarter, revenue climbed approximately 38% year over year to about $753 million, supported by record testing volumes and improving average selling prices, and the company raised its full-year revenue outlook to $2.85 billion to $2.91 billion.
Recent weeks have featured a series of regulatory and clinical milestones, including a U.S. FDA (Food and Drug Administration) Breakthrough Device designation for its multi-cancer early detection assay and earlier approvals positioning Signatera in bladder cancer, colorectal cancer, and European markets. The stock has trended toward its 52-week high on a roughly 75% year-to-date gain, reflecting strong sentiment and a transition to profitability. Momentum has been relatively steady, though the shares remain volatile and sensitive to reimbursement and pricing headlines.
Trending AI Robots
For traders seeking a systematic edge across names like these, Tickeron's Trending AI Robots page offers a curated view of the platform's most relevant automated strategies. Tickeron hosts hundreds of AI Trading Bots covering thousands of tickers, each with distinct trading styles, timeframes, performance statistics, and risk profiles. Because not every bot suits every market regime, only those best aligned with current conditions earn a place in this featured section, where users can review key metrics such as historical win rates, trade frequency, and profit factors across various strategies. Whether you prefer momentum, swing, or longer-horizon approaches, exploring the Trending AI Robots can help you identify automated tools matched to today's market environment.
Head-to-Head Comparison
At a business-model level, the two companies operate in different corners of healthcare. GKOS sells implantable devices and therapies with high gross margins but significant research and development and commercial spending, leaving it unprofitable as it scales iDose TR and Epioxa. NTRA generates recurring, high-volume testing revenue and has already crossed into profitability, giving it a more mature financial profile despite its smaller operating history in some segments.
Growth drivers also differ. GKOS's expansion hinges on physician adoption of interventional glaucoma procedures and the rollout of a new corneal therapy, while NTRA's trajectory depends on expanding Signatera indications, international approvals, and progress toward early cancer detection. From a momentum standpoint, both stocks have outperformed the market, but NTRA has shown more consistent trend continuity near highs, whereas GKOS has experienced sharper episodic drawdowns tied to insider transactions and reimbursement concerns. Risk factors are not symmetrical: GKOS faces payer-coverage and competitive device dynamics, while NTRA contends with diagnostic pricing pressure and competitive threats in a consolidating oncology diagnostics field.
Tickeron AI Verdict
Based on observable factors such as trend consistency, financial stability, and the breadth of near-term catalysts, Tickeron's AI would likely currently favor NTRA over GKOS. NTRA's established profitability, sustained uptrend near 52-week highs, and a pipeline of regulatory and guideline milestones present a comparatively smoother trend profile. GKOS offers compelling growth and product momentum but carries more visible volatility and an unprofitable near-term structure that could weigh on relative positioning. This assessment is probabilistic rather than definitive, reflecting the possibility that market conditions or company-specific developments could shift the balance between the two names.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GKOS is a Buy and NTRA is a Hold.
GKOS in upward trend: price rose above 50-day moving average on October 20, 2026
GKOS moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 34 of 36 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on GKOS as a result. In 76 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for GKOS just turned positive on October 02, 2026. Looking at past instances where GKOS's MACD turned positive, the stock continued to rise in 45 of 58 cases over the following month. The odds of a continued upward trend are 78%.
The 10-day moving average for GKOS crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +33.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where GKOS advanced for three days, in 248 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 252 of 314 cases where GKOS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The 10-day RSI Indicator for GKOS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In 33 of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at 75%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 53 of 68 cases where GKOS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GKOS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
GKOS broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 16 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. GKOS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.395) is normal, around the industry mean (4.142). P/E Ratio (-68.627) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (12.570) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (15.456) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 87 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
NTRA in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 05, 2026
NTRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 34 cases where NTRA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for NTRA's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRA advanced for three days, in 246 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NTRA as a result. In 80 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for NTRA turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 38 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.
NTRA moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
The Aroon Indicator for NTRA entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (24.585) is normal, around the industry mean (67.298). NTRA's P/E Ratio (-230.126) is considerably lower than the industry average of (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (17.857) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 25 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. NTRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
GKOS | NTRA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 87 Overvalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 16 | 25 | |
SMR RATING 1..100 | 96 | 94 | |
PRICE GROWTH RATING 1..100 | 34 | 44 | |
P/E GROWTH RATING 1..100 | 87 | 71 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (4) in the Biotechnology industry is significantly better than the same rating for GKOS (87) in the Medical Specialties industry. This means that NTRA’s stock grew significantly faster than GKOS’s over the last 12 months.
GKOS's Profit vs Risk Rating (16) in the Medical Specialties industry is in the same range as NTRA (25) in the Biotechnology industry. This means that GKOS’s stock grew similarly to NTRA’s over the last 12 months.
NTRA's SMR Rating (94) in the Biotechnology industry is in the same range as GKOS (96) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to GKOS’s over the last 12 months.
GKOS's Price Growth Rating (34) in the Medical Specialties industry is in the same range as NTRA (44) in the Biotechnology industry. This means that GKOS’s stock grew similarly to NTRA’s over the last 12 months.
NTRA's P/E Growth Rating (71) in the Biotechnology industry is in the same range as GKOS (87) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to GKOS’s over the last 12 months.
| GKOS | NTRA | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 75% | 3 days ago 86% |
| Stochastic ODDS (%) | 3 days ago 78% | 3 days ago 87% |
| Momentum ODDS (%) | 5 days ago 83% | 3 days ago 83% |
| MACD ODDS (%) | 6 days ago 78% | 3 days ago 76% |
| TrendWeek ODDS (%) | 3 days ago 71% | 3 days ago 76% |
| TrendMonth ODDS (%) | 3 days ago 78% | 3 days ago 78% |
| Advances ODDS (%) | 11 days ago 78% | 5 days ago 79% |
| Declines ODDS (%) | 24 days ago 67% | 3 days ago 75% |
| BollingerBands ODDS (%) | 3 days ago 70% | 3 days ago 90% |
| Aroon ODDS (%) | 3 days ago 80% | 3 days ago 83% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GKOS’s FA Score shows that 1 FA rating(s) are green while NTRA’s FA Score has 2 green FA rating(s).
- GKOS’s FA Score: 1 green, 4 red.
- NTRA’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GKOS’s TA Score shows that 6 TA indicator(s) are bullish while NTRA’s TA Score has 4 bullish TA indicator(s).
- GKOS’s TA Score: 6 bullish, 4 bearish.
- NTRA’s TA Score: 4 bullish, 5 bearish.
Price Growth
GKOS (@Medical/Nursing Services) experienced а -5.55% price change this week, while NTRA (@Medical Specialties) price change was -25.01% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -3.27%. For the same industry, the average monthly price growth was -8.05%, and the average quarterly price growth was -7.48%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -6.42%. For the same industry, the average monthly price growth was -7.90%, and the average quarterly price growth was +34.49%.
Reported Earning Dates
GKOS is expected to report earnings on Feb 25, 2027.
NTRA is expected to report earnings on Mar 04, 2027.
Industries' Descriptions
@Medical/Nursing Services (-3.27% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-6.42% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
GKOS and
Correlation & Price change
A.I.dvisor indicates that over the last year, GKOS has been loosely correlated with ISRG. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if GKOS jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To GKOS | 1D Price Change % | ||
|---|---|---|---|---|
| GKOS | 100% | +2.01% | ||
| ISRG - GKOS | 51% Loosely correlated | -3.36% | ||
| NTRA - GKOS | 48% Loosely correlated | -14.59% | ||
| RDNT - GKOS | 48% Loosely correlated | -2.58% | ||
| TWST - GKOS | 46% Loosely correlated | +0.15% | ||
| ALGN - GKOS | 43% Loosely correlated | +4.16% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| CHZ.X | 0.011357 | -0.000116 | -1.01% |
| Chiliz cryptocurrency | |||
| XMR.X | 600.452300 | -9.863464 | -1.62% |
| Monero cryptocurrency | |||
| POWR.X | 0.052903 | -0.001041 | -1.93% |
| Powerledger cryptocurrency | |||
| POND.X | 0.001186 | -0.000025 | -2.08% |
| Marlin cryptocurrency | |||
| PYR.X | 0.015234 | -0.006128 | -28.69% |
| Vulcan Forged (PYR) cryptocurrency | |||